Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi (IST:ONCSM)
Turkey · Delayed Price · Currency is TRY 99.70
+4.05 (4.23%)
At close: Oct 6, 2026
IST:ONCSM Income Statement
Financials in millions TRY. Fiscal year is January - December.
Millions TRY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 734.91 | 709.08 | 490.18 | 347.24 | 292.94 | 127.99 | |
Revenue Growth | 3.23% | 44.66% | 41.16% | 18.54% | 128.88% | - |
Cost of Revenue | 307.33 | 389.24 | 308.87 | 295.57 | 192.23 | 39.65 |
Gross Profit | 427.58 | 319.83 | 181.31 | 51.67 | 100.71 | 88.34 |
Selling, General & Admin | 177.92 | 158.41 | 163.06 | 116.73 | 65.92 | 15.73 |
Research & Development | 6.36 | 1.24 | - | - | - | - |
Other Operating Expenses | 9.67 | 7.52 | 11.23 | 21.05 | 1.78 | 2.25 |
Operating Expenses | 193.95 | 167.17 | 174.29 | 137.78 | 67.69 | 17.97 |
Operating Income | 233.63 | 152.66 | 7.02 | -86.11 | 33.01 | 70.37 |
Interest Expense | -50.55 | -32.25 | -45.61 | -14.25 | -2.03 | -2.61 |
Interest & Investment Income | 2.71 | 7.91 | 22.3 | 25.74 | - | 11.19 |
Currency Exchange Gain (Loss) | -1.04 | 1.29 | 0.09 | -8.61 | 6.51 | 2.55 |
Other Non Operating Income (Expenses) | -62.25 | -57.15 | -50.34 | -54.43 | -37.17 | -0.18 |
EBT Excluding Unusual Items | 122.5 | 72.46 | -66.53 | -137.66 | 0.32 | 81.32 |
Gain (Loss) on Sale of Investments | - | - | - | -0.36 | - | - |
Legal Settlements | 1.28 | 0.93 | 0.01 | 1.85 | -2.82 | -0.9 |
Pretax Income | 123.78 | 73.39 | -66.52 | -136.17 | -2.5 | 80.41 |
Income Tax Expense | 53.14 | 23 | 10.93 | -20.94 | 18.27 | 8.68 |
Net Income | 70.64 | 50.39 | -77.45 | -115.23 | -20.76 | 71.73 |
Net Income to Common | 70.64 | 50.39 | -77.45 | -115.23 | -20.76 | 71.73 |
Net Income Growth | 524.34% | - | - | - | - | - |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 12 | 0 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 12 | 0 |
Shares Change | - | - | - | 96.60% | 5025.57% | - |
EPS (Basic) | 2.96 | 2.11 | -3.25 | -4.83 | -1.71 | 303.08 |
EPS (Diluted) | 2.96 | 2.11 | -3.25 | -4.83 | -1.71 | 303.08 |
EPS Growth | 524.34% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 21.97 | 8.44 | 83.57 | -82.5 | 26.67 | 40.76 |
Free Cash Flow Per Share | 0.92 | 0.35 | 3.50 | -3.46 | 2.20 | 172.23 |
Dividend Per Share | - | - | - | - | 0.415 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 58.18% | 45.11% | 36.99% | 14.88% | 34.38% | 69.02% |
Operating Margin | 31.79% | 21.53% | 1.43% | -24.80% | 11.27% | 54.98% |
Profit Margin | 9.61% | 7.11% | -15.80% | -33.18% | -7.09% | 56.05% |
Free Cash Flow Margin | 2.99% | 1.19% | 17.05% | -23.76% | 9.10% | 31.85% |
EBITDA | 285.77 | 208 | 65.6 | -38.44 | 65.62 | 77.08 |
EBITDA Margin | 38.88% | 29.33% | 13.38% | -11.07% | 22.40% | 60.23% |
D&A For EBITDA | 52.13 | 55.34 | 58.58 | 47.66 | 32.61 | 6.71 |
EBIT | 233.63 | 152.66 | 7.02 | -86.11 | 33.01 | 70.37 |
EBIT Margin | 31.79% | 21.53% | 1.43% | -24.80% | 11.27% | 54.98% |
Effective Tax Rate | 42.93% | 31.34% | - | - | - | 10.80% |